Share Twitter LinkedIn Facebook Email Sattva Neelapu, MD Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, discusses The Future Of CAR-T Therapies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com
ASH 2025 Lymphoma Highlights: Epcoritamab, S1826, Mosunetuzumab & ctDNA | Dr. Sworder ASH 6 Mins Read
2025 Leukemia / Lymphoma Updates with Aaron Goodman, MD – UC San Diego – MOASC Hematologic Malignancies 6 Mins Read
FDA Approves Adcetris / brentuximab vedotin + lenalidomide & rituximab in relapsed or refractory LBCL: Could This Change Standard Care? Lymphoma 2 Mins Read